What semaglutide is made from — and why it matters

The human hormone semaglutide was built from

GLP-1 is released by cells in the small intestine within minutes of eating. It triggers insulin secretion, suppresses glucagon, slows how quickly the stomach empties, and signals the brain's appetite centres that food has arrived. The body's own GLP-1, however, is broken down by an enzyme called DPP-4 within roughly two minutes, too short to be clinically useful as a drug.

Novo Nordisk's scientists took the 30-amino-acid GLP-1 sequence and made two key modifications. First, they swapped one amino acid (alanine at position 8) for the amino acid alpha-amino-isobutyric acid, blocking the site where DPP-4 attacks the molecule. Second, they attached a C18 fatty di-acid chain to a lysine residue via a short linker. That chain anchors semaglutide loosely to albumin (the most abundant protein in plasma) creating a reservoir that releases the active molecule slowly. The result is a half-life of approximately one week, which is why a single weekly injection is enough to maintain therapeutic levels in the blood. This structural engineering is why asking what semaglutide is made out of has a precise molecular answer, not a vague one.

The full manufacturing process relies on yeast cells (Saccharomyces cerevisiae) that have been genetically programmed to express the peptide backbone. After fermentation, the protein is harvested, purified, and the fatty acid chain is attached through further chemical synthesis steps. The final molecule shares about 94% sequence identity with human GLP-1, close enough to bind the same receptor, different enough to last all week.

What the clinical trial evidence tells us about this engineered molecule

Understanding the manufacturing origin helps make sense of the trial results. Because the molecule is a close structural relative of the body's own satiety hormone, its effects in large trials were consistent and biologically coherent. The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with obesity and no diabetes and found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg weekly dose, compared with roughly 2.4% with placebo, alongside lifestyle changes.

A question our prescribers hear most weeks is whether the lab-made origin of semaglutide makes it less "natural" or more risky than a herbal supplement. The answer is the opposite: because its structure is precisely defined and reproduced through a tightly regulated manufacturing process, the consistency of each batch is verifiable in a way that plant extracts simply cannot match. Regulatory oversight by the MHRA, which licences Wegovy for weight management in the UK, covers both the molecule's purity and its manufacturing standards.

For context on how semaglutide compares with tirzepatide (which targets a second gut-hormone receptor (GIP) alongside GLP-1) the semaglutide overview page sets out the licensed indications and what the evidence says about each.

Why the fatty acid chain affects more than just dosing frequency

The albumin-binding mechanism does more than extend the drug's half-life. Because semaglutide circulates loosely bound to albumin rather than freely in plasma, it is less likely to be filtered by the kidneys, which further slows clearance. It also means semaglutide distributes differently from small-molecule drugs: it reaches the hypothalamus and brainstem appetite centres through fenestrated capillaries, reinforcing the central appetite-suppression effect that makes GLP-1 receptor agonists effective for weight management.

The same chemistry affects how the drug interacts with other medicines. NHS England's guidance on weight-management injections notes that because semaglutide slows gastric emptying, it can affect the absorption rate of oral medicines taken at the same time, a practical consideration your prescriber will factor into your assessment. For people on oral contraceptives, this is worth discussing; tirzepatide carries a specific four-week caution on pill absorption at initiation and each dose increase, while the evidence for semaglutide is less definitive, but it still merits a conversation.

The albumin-binding design is also responsible for semaglutide's relatively long wash-out period after stopping treatment. The molecule continues releasing from albumin stores for several weeks, which is clinically relevant for anyone planning surgery or considering pregnancy. Pricing context for Wegovy, including how private prescription costs break down, is covered separately on the Wegovy prices page.

Novo Nordisk's role and what it means for supply

Semaglutide is wholly owned and manufactured by Novo Nordisk, a Danish pharmaceutical company that has produced insulin and peptide hormones for over a century. The manufacturing process for semaglutide is considerably more complex than small-molecule chemical synthesis: it requires biological fermentation, peptide purification, and precision chemical modification, all carried out under pharmaceutical Good Manufacturing Practice (GMP) conditions. That complexity is one reason the supply chain has, at times, struggled to keep pace with demand since Wegovy was launched in the UK.

For UK patients, medicines are supplied exclusively through the licensed UK supply chain. Understanding who made semaglutide also matters from a counterfeiting perspective: the MHRA has warned publicly about fake weight-loss pens sold without a prescription, and the structural complexity of semaglutide makes high-quality counterfeiting difficult but not impossible. Buying from a pharmacy you can verify on the GPhC register is the only reliable safeguard. If you are ready to take the next step, speaking to our prescribers at our free consultation page is where that process begins.